CervoMed (DP8) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DP8 Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

CervoMed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DP8 Stock 12 Month Forecast

Average Price Target

€13.80

▲(544.97% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for CervoMed in the last 3 months. The average price target is €13.80 with a high forecast of €22.26 and a low forecast of €6.23. The average price target represents a 544.97% change from the last price of €2.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","12":"€12","23":"€23","6.5":"€6.5","17.5":"€17.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.26201675,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€22.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.802450385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.23336469,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.5,12,17.5,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,4.1124628269230765,5.624925653846153,7.13738848076923,8.649851307692307,10.162314134615384,11.674776961538461,13.187239788461538,14.699702615384615,16.212165442307693,17.72462826923077,19.237091096153847,20.749553923076924,{"y":22.26201675,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,3.461726952692308,4.323453905384616,5.185180858076923,6.0469078107692305,6.908634763461539,7.770361716153847,8.632088668846153,9.493815621538461,10.35554257423077,11.217269526923078,12.078996479615384,12.940723432307692,{"y":13.802450385,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,2.8794895915384617,3.158979183076923,3.4384687746153846,3.7179583661538462,3.997447957692308,4.2769375492307695,4.55642714076923,4.835916732307693,5.115406323846154,5.394895915384616,5.674385506923077,5.9538750984615385,{"y":6.23336469,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€22.26

Average Price Target€13.80

Lowest Price Target€6.23

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

€22.26

Buy

940.28%

Upside

Reiterated

10/19/26

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), CervoMed (CRVO)

Sumant Kulkarni

Canaccord Genuity

€16.03

Buy

649.00%

Upside

Reiterated

10/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Boobalan Pachaiyappan

Roth MKM

€6.23

Buy

191.28%

Upside

Reiterated

10/13/26

Roth MKM Reaffirms Their Buy Rating on CervoMed (CRVO)

Boris Peaker

JonesTrading

€10.69

Buy

399.33%

Upside

Reiterated

09/28/26

CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated

Daniil Gataulin

Chardan Capital

€18.7

Buy

773.84%

Upside

Reiterated

05/17/26

Analysts Offer Insights on Healthcare Companies: Urogen Pharma (NASDAQ: URGN) and CervoMed (NASDAQ: CRVO)

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Initiated

12/18/25

CervoMed initiated with an Overweight at Cantor FitzgeraldCervoMed initiated with an Overweight at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

€22.26

Buy

940.28%

Upside

Reiterated

10/19/26

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), CervoMed (CRVO)

Sumant Kulkarni

Canaccord Genuity

€16.03

Buy

649.00%

Upside

Reiterated

10/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Boobalan Pachaiyappan

Roth MKM

€6.23

Buy

191.28%

Upside

Reiterated

10/13/26

Roth MKM Reaffirms Their Buy Rating on CervoMed (CRVO)

Boris Peaker

JonesTrading

€10.69

Buy

399.33%

Upside

Reiterated

09/28/26

CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated

Daniil Gataulin

Chardan Capital

€18.7

Buy

773.84%

Upside

Reiterated

05/17/26

Analysts Offer Insights on Healthcare Companies: Urogen Pharma (NASDAQ: URGN) and CervoMed (NASDAQ: CRVO)

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Initiated

12/18/25

CervoMed initiated with an Overweight at Cantor FitzgeraldCervoMed initiated with an Overweight at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

ONCBeOne Medicines

IRLAIRulya Therapeutics

IDYAIDEAYA Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CervoMed

3 Months

Boobalan PachaiyappanRoth MKM

Success Rate

5/14 ratings generated profit

Average Return

+18.69%

Copying Boobalan Pachaiyappan's trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of +18.69% per trade.

1 Year

Boobalan PachaiyappanRoth MKM

Success Rate

2/14 ratings generated profit

Average Return

-19.65%

Copying Boobalan Pachaiyappan's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -19.65% per trade.

2 Years

Boobalan PachaiyappanRoth MKM

Success Rate

1/14 ratings generated profit

Average Return

-42.34%

Copying Boobalan Pachaiyappan's trades and holding each position for 2 Years would result in 7.14% of your transactions generating a profit, with an average return of -42.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DP8 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DP8 has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DP8 average Analyst price target in the past 3 months is 13.80.

Each month's total comprises the sum of three months' worth of ratings.

DP8 Financial Forecast

DP8 Earnings Forecast

Next quarter’s earnings estimate for DP8 is -€0.43 with a range of -€0.64 to -€0.20. The previous quarter’s EPS was -€0.56. DP8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DP8 has Performed in-line its overall industry.

DP8 Sales Forecast

Next quarter’s sales forecast for DP8 is €43.99K with a range of €0.00 to €263.91K. The previous quarter’s sales results were €0.00. DP8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DP8 has Performed in-line its overall industry.

DP8 Stock Forecast FAQ

What is DE:DP8’s average 12-month price target, according to analysts?

Based on analyst ratings, CervoMed’s 12-month average price target is 13.80.

What is DE:DP8’s upside potential, based on the analysts’ average price target?

CervoMed has 544.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CervoMed a Buy, Sell or Hold?

CervoMed has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is CervoMed’s share price target?

The average share price target for CervoMed is 13.80. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €22.26 ,and the lowest forecast is €6.23. The average share price target represents 544.97% Increase from the current price of €2.14.

What do analysts say about CervoMed?

CervoMed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of CervoMed?

To buy shares of DE:DP8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

CervoMed (DP8) Stock Forecast & Price Target

DP8 Analyst Ratings

DP8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CervoMed

DP8 Analyst Recommendation Trends

DP8 Financial Forecast

DP8 Earnings Forecast

DP8 Sales Forecast

DP8 Stock Forecast FAQ

Detailed List of Analyst Forecasts